ARTICLE | Clinical News
Ranexa: Phase III data
April 26, 2004 7:00 AM UTC
Previously reported result from the Phase III MARISA trial in 191 angina patients showed Ranexa increased symptom-limited exercise duration (p<0.005). Ranexa also increased the secondary endpoint of t...